HomeMarket NewsFour Pharma stocks that should be on your radar ahead of Tuesday’s trade
Losses continued for Sun Pharma’s research division, although they were narrower compared to the same quarter last year. Sanofi India’s results were also lower from last year.
Shares of four Indian drugmakers will be in focus on Tuesday, August 5, as they will be reacting to their quarterly results that were reported after market hours on Monday.
Here’s a look at these four stocks:
Aurobindo Pharma
The company’s US sales stood at $408 million compared to $470 million in March, mainly due to lower sales of the Revlimid generic. Growth during the quarter was driven by Europe and Growth Markets.
Revenue for the quarter increased by 4% from last year to ₹7,868 crore, but was below the CNBC-TV18 poll of ₹8,214 crore.
Aurobindo’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA), margins and net profit was also significantly below the CNBC-TV18 poll, and all these parameters were lower on a year-on-year basis.
European sales increased by 18% from last year, while Growth markets grew by 9%.
OneSource
The company reported a net loss during the quarter, which was narrower than last year but most other parameters, even though they were higher year-on-year, came off sharply on a sequential basis.
Revenue increased 12% from last year but fell 23% sequentially. EBITDA more than halved from the March quarter but was up 38% from last year. Margins narrowed to 27% from 42.8% in March
SPARC
Losses continued for Sun Pharma’s research division, although they were narrower compared to the same quarter last year.
SPARC’s loss narrowed to ₹51.93 crore, down from the ₹95.85 crore loss it reported last year and the ₹60.16 crore net loss it reported in March.
Revenue for the quarter fell 43% from last year and 65% sequentially. EBITDA loss also narrowed year-on-year and quarter-on-quarter.
Sanofi India
The India unit of the MNC drugmaker also reported results on Monday, which were lower on a year-on-year basis, across parameters.
Revenue for the quarter fell 12%, EBITDA was down 18%, while margins contracted to 23.4% from 25% last year.
Sanofi follows a calendar year format for its results, which means this was their second quarter results announcement.
Aurobindo Pharma’s shares have declined 8% in the last one month, while those of OneSource, Sanofi and SPARC have declined 4%, 10% and 6% respectively during the same timeframe.
